Cytomegalovirus (CMV) infection in clinical settings other than the allogeneic transplant represents a poorly explored issue. Thus, we performed a comprehensive review of the medical literature about CMV infection in patients undergoing autologous hematopoietic stem cell transplant and in other nontransplant-related hematologic patients. In autologous hematopoietic stem cell transplant, a CMV reactivation is reported to occur in up to 41% of CMV seropositive patients, when a prospective monitoring of antigenemia and/or viremia by polymerase chain reaction was adopted. However, more contained frequencies, up to 12%, have been reported when the monitoring criteria were based on a clinically driven diagnostic strategy. The most relevant risk factors appear to be CD34 + selected autografts, total body irradiation, and prior treatment with Alemtuzumab, Fludarabine, or Bortezomib, respectively. Other possible risk factors (ie, prior treatment with Rituximab, T-cell lymphomas, and pretransplant HBcIgG seropositivity) are still debated. In nontransplant settings, the data are very heterogeneous; thus, CMV infection incidence and risk factors are more difficult to establish. Overall, the rate of CMV infection/reactivation ranges between 2 and 67%. High-dose steroids, advanced disease, poor performance status, and treatment with Alemtuzumab, Fludarabine, Bortezomib, and Rituximab appear as the most relevant, though putative, risk factors. Intravenous Ganciclovir represents the gold standard for first-line treatment of CMV infection in these patients. Oral Valganciclovir and Foscarnet are other possible options. Extensive prophylaxis and preemptive therapy are not generally recommended, with the exception of high-risk patients.
| THE BIOLOGY OF CYTOMEGALOVIRUS INFECTION
Cytomegalovirus is a DNA virus belonging to the herpesviridae family, characterized by a slow growth and a considerably large genomic size, coding for approximately 200 proteins. Cytomegalovirus is capable to infect a variety of different host cells, including endothelial, epithelial, smooth muscle, and blood cells. 9 Following entry of the viral particle into the host cells, virion components and viral genome are transported to the nucleus where viral transcription and replication are reported to occur in about 12 hours after infection. The replication cycle of CMV is typically slow and leads to virus dissemination and transmission. 10 Cytomegalovirus infection usually occurs in juvenile age and is generally asymptomatic. However, although immunologically suppressed, the infection is not cleared and the virus remains in the human body after primary infection. As a consequence, up to 90% of the healthy population in Western countries is positive for CMV IgG. Despite the vast amount of studies aimed at dissecting the mechanism of latency as well as at identifying the cellular recipients and sites harbouring the virus reservoir, the physiopathological basis of virus persistence remains elusive, as yet. However, some evidence point to the granulocyte-monocyte-macrophage lineage as a possible reservoir of CMV latency. 11 T-cell mediated immunity plays a crucial role in controlling CMV infection and replication. In particular, the generation of CD8+ cytotoxic T-cells against virus antigens (ie, IE-1, IE-2, and pp65) appears as the most important adaptive immune response. [12] [13] [14] Indeed, the reconstitution of CMV-specific CD8+ Tcells after hematopoietic stem cell and solid organ transplants correlates with CMV disease control, 15, 16 whereas the occurrence of dysfunctional antigen-specific CD8+ T-cells is associated with CMV reactivation. 17 CD4+ T-cell-specific response appears also involved in controlling CMV infection and reactivation, and some data suggested that the loss of a specific CD4+ T-cell response after allo-HSCT is associated with late CMV disease. 18 Less clear and studied is the role of humoral and innate immunity. As for the first one, some data seem to suggest a possible role of anti-CMV antibodies in limiting disease severity. 1, 19 The innate immune system is instead thought to act in controlling CMV trough 2 main mechanisms: cellular inflammatory cytokine/chemokine production, directly triggered by CMV and natural-killer cell response. In support of this notion, several studies indicated that CMV reactivation could be associated to polymorphisms in toll-like receptor 2, chemokine receptor 5, interleukin 10, and monocyte chemoattractant protein 1 20, 21 and to an impaired natural-killer cell response. 22 
| CLINICAL MANIFESTATIONS OF CYTOMEGALOVIRUS INFECTION/ REACTIVATION
Due to its relevance and complexity of the diagnostic procedures to properly identify CMV infection, reactivation, and disease, international guidelines were issued in 2002. 23 Moreover, a recent update version has been produced for use in clinical trials. 24 Briefly, these can be summarized as follows:
• Cytomegalovirus infection: isolation of CMV or detection of viral proteins and/or nucleic acid in body fluid or tissue specimens.
• Cytomegalovirus detection in blood: viremia is defined as the isolation of CMV by in vitro culture; antigenemia is defined as the detection of pp65 in leukocytes; DNAemia is defined as the detection of DNA in samples of plasma or whole blood through polymerase chain reaction (PCR)-based techniques, hybrid capture, or branched-chain DNA analysis.
• Primary infection: a new detection in a previously seronegative patient.
• Recurrent infection: a new detection of CMV infection in a patient with a previously documented infection. A recurrent infection could be determined by the same or by a different virus strain (defined reactivation and reinfection, respectively).
• • Cytomegalovirus end-organ disease: a CMV infection directly responsible for organ damage.
• Cytomegalovirus pneumonia: defined by the presence of pulmonary disease combined by the detection of CMV in bronchoalveolar lavage (BAL) fluid or lung tissue samples by virus isolation, histopathological testing, immunohistochemical analysis, or in situ hybridization. The detection by CMV PCR alone is considered to be too sensitive and therefore not conclusive for the diagnosis.
However, in recent years, some studies showing the highly predictive value of CMV PCR detection on BAL have been published. 25 Very recently, 2 independent studies showed that a noninvasive bronchial washing procedure could replace an invasive lung biopsy in the diagnosis of CMV pneumonia, avoiding the risk of biopsyrelated bleeding and using a specific cutoff of DNA viral load as assessed by quantitative PCR. 26, 27 Nevertheless, although these data are quite promising, a standardized quantitative PCR cutoff remains to be established; thus, this technique still does not fulfil the criteria for routine clinical application. A commonly used classification for CMV pneumonia is summarized in Table 1 .
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• Cytomegalovirus gastrointestinal disease: defined by the identifica- 
| DIAGNOSTIC METHODS AND MONITORING STRATEGIES
Serologic determination of CMV IgG and IgM does not fulfil the criteria for diagnosis of CMV infection/reactivation in patients with hematologic malignancies. 28 In allo-HSCT, only the detection of CMV in blood may predict the development of a CMV disease. 32 Thus, the most reliable tests for CMV assessment are based on the determination of pp65 antigenemia, viral DNA, or mRNA. Even though all these techniques appear similarly useful, [33] [34] [35] CMV detection by PCR is the most widely used assay, particularly in leukopenic patients, being highly sensitive and thus more informative in providing potentially important prognostic information. 36 Detection of mRNA by RT-PCR is also a valid and rapid assay, although a less used option. 37 Finally, the shell vial technique (rapid culture), which consists in the detection of CMV IE proteins in cultured cells using monoclonal antibodies, is not routinely used for CMV detection in blood but is widely used for assessment on BAL. 1 Considering the diagnostic strategies, 2 main different approaches have emerged so far. The first regards the prospective surveillance strategy for early detection of CMV reactivation, which is recommended in allo-HSCT to promptly start a preemptive antiviral treatment to reduce the risk of progression from infection to disease. 38 On the contrary, a routine surveillance is being considered unnecessary in other hematologic patients because of the low likelihood of progression from infection to disease, with the exception of patients receiving ASCT with CD34+-selected cells and those treated with Fludarabine, Cladribine, or Alemtuzumab. 28 In other cases, a clinically driven diagnostic approach is followed, in which CMV is investigated Tables 2 and 3 summarize a proposal of risk-stratification assessment for CMV reactivation based on literature data and the diagnostic methods and strategies for infection monitoring in hematologic patients, respectively. We included into this group high-risk ASCT/nontransplant patients and low-risk allo-HSCT patients.
| CYTOMEGALOVIRUS INFECTION IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT
Hematologic patients treated with high-dose chemotherapy and undergoing ASCT were historically considered at a low risk for CMV infection/reactivation. However, a first group of studies performed in the 1990s showed a not irrelevant figure of CMV reactivation rates, approximately reaching a frequency of 40% in seropositive patients. 40, 41 Subsequently, other reports confirmed the relevance of this issue, although reporting a variable rate of incidence ranging between 30 to 40% and 1 to 13%, according to different diagnostic strategies. 5, [42] [43] [44] [45] [46] [47] [48] [49] Even though all these studies showed a significant reactivation rate of CMV infection in patients undergoing ASCT, CMV disease was a rare event, although representing a serious life-threatening risk, with a clinical course and mortality rates similar to those observed after allo-HSCT. 1 On the basis of the low Table 4 summarizes the main reports published during the last 20 years. Taken together, the results from these studies indicate that the incidence of CMV infection in hematologic patients undergoing ASCT may range between frequencies of 17% and 41%, when a prospective monitoring by antigenemia and/or viremia by PCR was adopted. Conversely, the frequencies are reported to range between 3% and 12% when a clinically driven strategy was applied, thus limiting the diagnosis only to the most relevant cases in terms of morbidity. Moreover, the overall analysis of these data does not clearly indicate a significant increase of CMV reactivation rate during the past 20 years, suggesting that the use of novel and more potent therapeutic agents has had only a modest impact on CMV infection/reactivation and overt disease.
In fact, the reported increase of CMV infection/reactivation occurrence in lymphoma patients undergoing ASCT after treatment with Rituximab needs further confirmation. 8, 52, 57 On the contrary, the evidence about the impact of Bortezomib in myeloma patients is more persuasive, 49, 58, 59, 63 and these data need to be confirmed by larger prospective studies. Nevertheless, even though CMV reactivation still represents an important complication, most cases are successfully managed with a specific antiviral treatment (often administered within outpatient clinical settings). Still, though rare, CMV end-organ disease remains a serious life-threatening event in autografted patients, with an incidence up to 4% as reported throughout the last 20 years, although it is showing a trend toward a significant improvement when considering the more recent studies. 3, 7, 8, 39, 52, [54] [55] [56] [57] [58] [59] Of note, overt CMV disease incidence and mortality appear similar irrespective to the diagnostic strategy adopted, further suggesting the limited usefulness of a prospective monitoring of CMV infection. 28 These findings are also in agreement with our recently updated results (Table 5) . 
Diagnostic Methods Comments
CMV DNAemia by PCR from plasma 32, 33, 36 More sensitive than antigenemia. Due to the high sensitivity, further validation of specific cutoff is needed for use in clinical practice.
pp65 antigenemia [33] [34] [35] Rapid semiquantitative assay. Some limitations in patients with low white blood cell count CMV mRNA by nucleic acid sequence-based amplification 37 Similar efficacy compared with the above cited techniques. However, less frequently used Shell vial technique (rapid culture) 1 Based on monoclonal antibodies directed toward CMV IE proteins in cultured cells. Useful for diagnosis of CMV pneumonia but not applicable for routine blood monitoring
Diagnostic strategies Comments
Prospective monitoring (surveillance) of CMV infection in peripheral blood performed twice weekly 38 Applied for very high risk patients (ie, allo-HSCT by cord blood donor)
Prospective monitoring (surveillance) of CMV infection in peripheral blood performed once weekly 1, 28, 38 Applied for other allo-HSCT patients until day 100. Continued after day 100 if risk factors for late CMV are present (ie, high-dose steroids and anti-T-cell agents) Applied also for hematologic patients outside the allogeneic transplant setting when fulfilling high-risk criteria (ie, CD34+-selected grafts, patients treated with Alemtuzumab, and patients undergoing ASCT after treatment with Fludarabine, Cladribine, high-dose steroids, and/or conditioned with TBI)
Clinically driven approach (CMV determination only in case of clinical suspicion of infection) 39 Patients undergoing ASCT, with the exclusion of high-risk patients (as defined above) Other hematologic patients allo-HSCT indicates allogeneic hematopoietic stem cell transplant; ASCT, autologous hematopoietic stem cell transplant; IE, immediately early; PCR, polymerase chain reaction; TBI, total body irradiation. These studies strongly suggest that an impaired T-cell immunity function, determined by Alemtuzumab, may represent a high risk factor for CMV infection/reactivation and that patients treated with this drug should be prospectively and carefully monitored. CMV infection or end-organ disease. 1 A preemptive strategy should be adopted in patients undergoing allo-HSCT and in high-risk patients, in settings other the allogeneic transplant. 1, 28, 98 In all other patients, CMV infection should be treated only when clinically symptomatic. Ganciclovir should be administered at the standard dosage of 5 mg/kg BID for 7 to 14 days followed by 5 mg/kg QD until indicator assays are negative for a minimum of 2 weeks. 1, 98 Oral Valganciclovir at the dosage of 900 mg BID for 7 to 14 days followed by a maintenance with 450 mg BID (at least 1 week or until indicator assays are negative) could be a valid alternative, particularly in patients with mild disease. 98, 99 However, due to their myelotoxic effect, a neutropenia can occur in almost 30% of patients receiving Ganciclovir or Valganciclovir, which may lead to an increase of secondary infections. 1, 98, 100, 101 Considering this aspect, intravenous Foscarnet might represent a preferable option in patients with severe cytopenia, despite its not optimal safety profile and the limited availability of data about its effectiveness for the treatment of CMV infection in settings other than allo-HSCT. 102 As for prophylaxis strategies, the current guidelines do not recommend a routine prophylaxis in patients with hematologic malignancies not undergoing allo-HSCT, with the only exception of high-risk patients undergoing autologous transplant and those treated with Alemtuzumab. 
| CONCLUSIONS
Cytomegalovirus infection represents a major concern for hematologists and a difficult challenge in many different clinical settings in addition to the allogeneic transplant. Even though its incidence does not seem to be consistently increased over the last 20 years and a CMV end-organ disease remains a rare event, with the exclusion of allotransplanted patients, clinicians should be aware of this relatively common complication in consideration of its life-threatening potential, especially in this era, which is offering an unprecedented, rich pipeline of entirely novel generations of immunosuppressive and pleiotropic therapeutic agents for the treatment of hematologic malignancies.
